General Clinical Chemistry Analyzers and Accessories
Abcam LM22A-4, neurotrophic BDNF mimetic, 50MG
MW 339.34 Da, Purity >98%. Small molecule BDNF mimetic displaying neurotrophic activity. Partial agonist at TrkB, activating TrkB signaling. Displaces BDNF (IC₅₀ = 47 nM) in binding assays. Prevents neuronal degeneration with equal efficacy to that of BDNF in in vitro models of neurodegenerative disease. Causes hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats, after in vivo administraton. Improves respiratory function in a mouse model of Rett syndrome.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Binimetinib, MEK1/2 inhibitor, 25MG
MW 441.2 Da, Purity >99%. Potent and selective allosteric inhibitor of MEK1/2. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ezetimibe, cholesterol absorption inhibitor, 20MG
MW 409.4 Da, Purity >98%. Potent selective cholesterol absorption inhibitor. Inhibits cholesterol absorption in the intestine by preventing uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter. Ezetimibe reduces plasma cholesterol levels from 964 to 374 mg/dL, from 726 to 231 mg/dL, and from 516 to 178 mg/dL in the western, low-fat, and cholesterol-free diet mice, respectively.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 10MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 1MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 25MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Qstatin, 25MG
MW 293.2 Da, Purity >=98%. A potent, and selective Vibrio QS inhibitor which affects Vibrio harveyi LuxR homologues, the well-conserved master transcriptional regulators for QS in Vibrio species. QStatin binds tightly to a putative ligand-binding pocket in SmcR, the LuxR homologue in V. vulnificus, and changes the flexibility of the protein, thereby altering its transcription regulatory activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CCG 1423, Rho pathway-mediated signaling inhibitor, 25MG
MW 454.7 Da, Purity >98%. Specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. Displays activity in several in vitro cancer cell functional assays. Potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, inhibits growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. Selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell lines. Acts at or downstream of MLK1 and upstream of SRF. Blocks MLK1 nuclear localization.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 100MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC 14012, Peptidomimetic C x CR4 antagonist, 5MG
MW 2066.4 Da, Purity >95%. TC 14012, Peptidomimetic CXCR4 antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 25MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement